Beverly Hills Private Wealth LLC Boosts Holdings in Becton, Dickinson and Company (NYSE:BDX)

Beverly Hills Private Wealth LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 53.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,161 shares of the medical instruments supplier’s stock after buying an additional 1,808 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $1,206,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in Becton, Dickinson and Company in the fourth quarter valued at $761,798,000. Nordea Investment Management AB increased its position in shares of Becton, Dickinson and Company by 277.3% during the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after purchasing an additional 1,423,353 shares during the last quarter. PineStone Asset Management Inc. raised its holdings in Becton, Dickinson and Company by 141.6% in the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after buying an additional 788,735 shares during the period. M&G Plc acquired a new position in Becton, Dickinson and Company in the first quarter valued at about $173,692,000. Finally, Bank of New York Mellon Corp boosted its stake in Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.9 %

BDX opened at $233.66 on Thursday. The business has a fifty day moving average price of $234.45 and a 200 day moving average price of $235.73. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $269.52. The stock has a market capitalization of $67.53 billion, a price-to-earnings ratio of 51.47, a PEG ratio of 1.90 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the previous year, the company posted $2.96 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on BDX shares. Evercore ISI reduced their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective for the company. Raymond James decreased their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, Citigroup lowered their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.